Analyzing Pain and Mental Health Trends in Young Individuals with Chronic Pain Amidst the COVID-19 Pandemic - Top-Institutions - MDSpire

Analyzing Pain and Mental Health Trends in Young Individuals with Chronic Pain Amidst the COVID-19 Pandemic

  • By

  • Fareha Nishat

  • Sarah Brennenstuhl

  • Nicole E. MacKenzie

  • Sakib Tariq

  • Kathryn A. Birnie

  • Melanie Noel

  • Chitra Lalloo

  • Sabine Soltani

  • Jennifer N. Stinson

  • April 29, 2026

  • 0 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    The Hospital for Sick Children (SickKids)
    The Hospital for Sick Children (SickKids)

    Toronto, Ontario

    Key Differentiators

    • Pediatric Pain Management
    • Child Psychiatry
    • Pediatric Psychology

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, California

    Key Differentiators

    • Pediatric Pain Research
    • Child and Adolescent Psychiatry
    • Behavioral Medicine

  • #3

    Boston Children's Hospital
    Boston Children's Hospital

    Boston, Massachusetts

    Key Differentiators

    • Pediatric Pain Medicine
    • Child Psychology
    • Psychiatry

  • #4

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania

    Key Differentiators

    • Pediatric Pain and Palliative Care
    • Child Psychiatry
    • Clinical Psychology

Original Source(s)

Analyzing Pain and Mental Health Trends in Young Individuals with Chronic Pain Amidst the COVID-19 Pandemic

  • by Fareha Nishat, Sarah Brennenstuhl, Nicole E. MacKenzie, Sakib Tariq, Kathryn A. Birnie, Melanie Noel, Chitra Lalloo, Sabine Soltani, Jennifer N. Stinson

  • April 29, 2026

Related Content

Acute liver failure and secondary TMA-like phenomenon following SARS-CoV-2 and Mycoplasma pneumoniae co-detection in a child: a case report

Assessing the association of physical distancing to avoid COVID-19 with health-related quality of life in immunocompromised adolescents: results from the cross-sectional observational EAGLE study

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.